Researchers at the Princess Margaret Cancer Centre in Toronto are launching a years-long research project to study liquid biopsies [1].
This initiative could fundamentally change post-treatment care by identifying patients who need further intervention while sparing others from costly and invasive procedures. By detecting microscopic traces of disease, the team aims to protect survivors from recurrence without subjecting all patients to aggressive therapies.
The project focuses on using blood tests to find tiny amounts of cancer remaining after patients have undergone treatment [2]. These liquid biopsies search for circulating tumor DNA, known as ctDNA, which can appear in the bloodstream even when traditional imaging cannot see a tumor [3].
Researchers are working on a large trial to determine if a blood test can detect these remaining cancer cells, a report from msn.com said [2]. The goal is to provide a more precise way to monitor patients and guide personalized therapy based on molecular evidence [3].
Liquid biopsies are particularly useful in monitoring for the progression of early-stage breast cancer [3]. By identifying ctDNA at molecular levels, doctors can better determine if a treatment was successful or if the disease is returning [3].
The Toronto-based team believes this approach will refine the balance between over-treating patients and missing early signs of relapse [1]. This long-term study represents a shift toward molecular monitoring in oncology, moving away from a one-size-fits-all approach to follow-up care [1].
Because the project is described as a years-long effort, the researchers expect to gather extensive data on how these tests correlate with long-term patient outcomes [1], [2].
“The project focuses on using blood tests to find tiny amounts of cancer remaining after patients have undergone treatment.”
The shift toward liquid biopsies represents a move toward 'precision oncology.' By detecting circulating tumor DNA, clinicians can move from a reactive model—treating cancer once it is visible on a scan—to a proactive model that identifies recurrence at the molecular level. If successful, this could reduce the systemic toxicity and financial burden associated with unnecessary chemotherapy or surgery for survivors who are already cancer-free.
